6.98
+2.50%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Evolus
From its filings with the US Securities and Exchange Commission
Evolus is based in Newport Beach, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker EOLS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $297.2m and a net loss of $51.6m. At that date it held total assets of $225.9m and shareholders' equity of −$23.1m. By business, Product revenue, net brought in 99.3% of revenue, followed by Service revenue at 0.7%.
We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products. By avoiding the regulatory burdens that accompany reimbursed products and pursuing an aesthetic-only non-reimbursed product strategy, we believe that we create flexibility to deliver a unique value proposition to our customers. We utilize this flexibility to drive customer adoption efforts through programs such as our consumer loyalty program, co-branded marketing programs, promotional events and pricing strategies.
Our current commercially available products and our product candidates represent two of the largest product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid (“HA”) gels.
Jeuveau® is a proprietary 900 kilodalton (“kDa”), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as “frown lines,” in adults. Jeuveau® offers a 900 kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). We believe aesthetic practitioners generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Feb 2018
- Employees
- 334
- Website
- evolus.com ↗
- Head office
- 520 NEWPORT CENTER DRIVE, NEWPORT BEACH, CA, 92660
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Vikram MalikIndependent Chairman of the Board, since 2018$281,740
- Mr. David MoatazediPresident, Chief Executive Officer, Director, since 2018$7.0m
- Ms. Tatjana MitchellChief Financial Officer
- Dr. Rui AvelarChief Medical Officer, Head - Research and Development$2.9m
- Mr. David GillIndependent Director$264,740
- Ms. Karah ParschauerIndependent Director$246,740
- Mrs. Brady StewartIndependent Director$241,740
- Mr. Albert WhiteIndependent Director$284,000
- Mr. Nareg SagherianInvestor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 38
- Environment
- 41
- Social
- 38
- Governance
- 35
- Women in the workforce
- 57%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Evolus Inc has a diverse and dedicated team of experienced professionals, allowing for a wide range of expertise and perspectives.
- The company's flagship product, Jeuveau, has been approved by the FDA and offers a competitive advantage in the aesthetics market.
- Evolus Inc has established strong relationships with key stakeholders, including healthcare professionals, medical spas, and distributors, enhancing its market presence.
Weaknesses
- Evolus Inc operates in a highly competitive industry, with well-established competitors, which may pose challenges in gaining market share.
- The company heavily relies on the success of Jeuveau, which could result in increased vulnerability to market fluctuations or potential product failures.
- Evolus Inc may face regulatory hurdles or legal issues that could delay product launches or negatively impact its reputation.
Opportunities
- Evolus Inc can leverage the growing demand for minimally invasive aesthetics procedures, presenting an opportunity for market expansion.
- The company can explore partnerships or collaborations with established players in the industry to further enhance its product portfolio and reach.
- Evolus Inc has the potential to expand its geographic presence by targeting new markets and regions with untapped growth potential.
Threats
- Evolus Inc faces regulatory risks, such as changes in government regulations or requirements, which could impact its ability to operate or market its products.
- The company is susceptible to the emergence of new competitive products or technologies, which may challenge its market positioning.
- Evolus Inc must navigate potential economic downturns or recessions, which could affect consumer spending power and demand for aesthetic treatments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.